엘리퀴스(아픽사반) 시장 규모, 점유율, 동향 분석 보고서 : 적응증별, 유통 채널별, 지역별, 부문별 예측(2025-2033년)

Eliquis (Apixaban) Market Size, Share & Trends Analysis Report By Indication (Atrial Fibrillation (AF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,323,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,722,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,520,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

엘리퀴스(아피사반) 시장 요약

세계 엘리퀴스(아픽사반) 시장 규모는 2024년에 207억 달러로 추정되며, 2025-2033년 연평균(CAGR) -2.2%로 2033년에는 188억 7,000만 달러에 달할 것으로 예측됩니다. 주요 원인은 특허 독점권 상실, 제네릭 의약품 경쟁 심화, 주요 시장 전반의 가격 하락입니다.

세계적으로 심방세동(AF)과 정맥혈전색전증(VTE)의 부담이 증가함에 따라 엘리퀴스(Apixaban) 시장의 주요 촉진요인으로 부상하고 있습니다. 심방세동은 뇌졸중의 위험을 크게 증가시키기 때문에 장기적인 예방을 위한 항응고제 사용이 증가하고 있습니다. 2022년 6월, Journal of Clinical Medicine 저널은 390만 명 이상의 성인 심방세동 환자를 대상으로 한 메타분석을 통해 아픽사반의 안전성과 유효성을 평가하였습니다. 이 연구에서 아픽사반은 다른 항응고제와 비교하여 뇌졸중 위험, 사망률, 대출혈이 낮고, 다른 항응고제와 비교하여 좋은 결과를 보였습니다. Eliquus는 우수한 안전성 프로파일과 최소한의 모니터링이 필요하기 때문에 선호되는 선택이 될 수 있습니다. 순환기내과 진료지침은 직접 경구용 항응고제 사용을 확대하여 1차의료 및 전문 의료에서 널리 채택되고 있습니다. 심방세동과 심방세동 및 VTE 사례가 증가함에 따라, 특히 노년층에서 심방세동과 VTE 사례가 증가함에 따라, 엘리퀴스와 같은 신뢰할 수 있고 투여하기 쉬운 항응고제에 대한 수요는 계속 증가하고 있습니다.

직접 경구용 항응고제로의 임상 관행의 변화는 엘리퀴스 시장에서의 입지를 강화하고 있습니다. 의료진은 DOAC의 예측 가능한 약동학, 고정 용량, 와파린보다 낮은 출혈 위험으로 인해 DOAC를 높이 평가했습니다. 엘리퀴스는 대규모 임상에서 우수한 결과를 보여 세계적으로 높은 처방률에 기여하고 있습니다. 환자들은 간편한 치료 요법을 통해 치료 순응도가 향상되고, 의료진 방문 횟수가 줄어드는 이점이 있습니다. 기존 항응고제에서 DOAC로의 전환이 가속화되는 가운데, 엘리퀴스는 세계 항응고제 시장에서 점유율을 확대할 수 있는 좋은 위치에 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 엘리퀴스(아픽사반) 시장 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 업계 분석 - Porter의 Five Forces 분석
  • PESTLE 분석
  • 파이프라인 분석
  • 특허 만료 분석
  • 가격 분석

제4장 엘리퀴스(아픽사반) 시장 : 적응증 비즈니스 분석

• 적응증 시장 점유율, 2024년 및 2033년
• 적응증 부문 대시보드
• 시장 규모, 예측, 동향 분석(적응증별, 2021-2033년)
• 심방세동(AF)
• 심부정맥 혈전증(DVT)
• 폐색전증(PE)
• 수술후 정맥혈전 색전증(VTE) 예방
• 기타

제5장 엘리퀴스(아픽사반) 시장 : 유통 채널 비즈니스 분석

• 유통 채널 시장 점유율, 2024년 및 2033년
• 유통 채널 부문 대시보드
• 시장 규모와 예측 및 동향 분석(유통 채널별, 2021-2033년)
• 병원 약국
• 소매 약국
• 온라인 약국

제6장 엘리퀴스(아픽사반) 시장 : 지역 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2033년
• 지역 시장 대시보드
• 시장 규모와 예측 동향 분석, 2021-2033년
• 북미
  • 국가별, 2021년-2033년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 참가자 개요
• 기업 시장 현황 분석
• 기업 분류
• 전략 매핑
• 기업 개요/상장기업
  • F. Hoffmann-La Roche Ltd.
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GSK plc
  • Novartis AG
  • AstraZeneca
  • Johnson &Johnson Private Limited
  • Bristol-Myers Squibb Company

LSH

영문 목차

영문목차

Eliquis (Apixaban) Market Summary

The global Eliquis (apixaban) market size was estimated at USD 20.70 billion in 2024 and is projected to reach USD 18.87 billion by 2033, with a decline of CAGR of -2.2% from 2025 to 2033, primarily due to loss of patent exclusivity, growing generic competition, and consequent price erosion across major markets.

The increasing global burden of atrial fibrillation (AF) and venous thromboembolism (VTE) has emerged as a major driver for the Eliquis (Apixaban) market. AF significantly raises the risk of stroke, prompting greater use of anticoagulants for long-term prevention. In June 2022, the Journal of Clinical Medicine published a meta-analysis of over 3.9 million adults with atrial fibrillation, assessing apixaban's safety and effectiveness. The study found that apixaban had favorable outcomes compared to other anticoagulants, with lower stroke risks, mortality, and major bleeding. Eliquis has become a preferred option due to its favorable safety profile and minimal need for monitoring. Clinical guidelines in cardiology have expanded the use of direct oral anticoagulants, leading to broader adoption across primary and specialty care. As AF and VTE cases rise, particularly among aging populations, the demand for reliable and easy-to-administer anticoagulants such as Eliquis continues to grow.

Shifts in clinical practice toward direct oral anticoagulants have strengthened Eliquis's market position. Healthcare providers value DOACs for their predictable pharmacokinetics, fixed dosing, and lower risk of major bleeding events than warfarin. Eliquis has shown superior results in large-scale trials, contributing to its high prescription rates worldwide. Patients benefit from simplified treatment regimens that improve adherence and reduce healthcare visits. As transitioning from traditional anticoagulants to DOACs accelerates, Eliquis is well-positioned to capture a growing share of the global anticoagulant market.

Global Eliquis (Apixaban) Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Eliquis (apixaban) market report based on indication, distribution channel, and region:

• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Atrial Fibrillation (AF)
• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)
• Post-Operative Venous Thromboembolism (VTE) Prophylaxis
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Eliquis (Apixaban) Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Eliquis (Apixaban) Market: Indication Business Analysis

• 4.1. Indication Market Share, 2024 & 2033
• 4.2. Indication Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
• 4.4. Atrial Fibrillation (AF)
  • 4.4.1. Atrial Fibrillation (AF) Market, 2021 - 2033 (USD Million)
• 4.5. Deep Vein Thrombosis (DVT)
  • 4.5.1. Deep Vein Thrombosis (DVT) Market, 2021 - 2033 (USD Million)
• 4.6. Pulmonary Embolism (PE)
  • 4.6.1. Pulmonary Embolism (PE) Market, 2021 - 2033 (USD Million)
• 4.7. Post-Operative Venous Thromboembolism (VTE) Prophylaxis
  • 4.7.1. Post-Operative Venous Thromboembolism (VTE) Prophylaxis Market, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Eliquis (Apixaban) Market: Distribution Channel Business Analysis

• 5.1. Distribution Channel Market Share, 2024 & 2033
• 5.2. Distribution Channel Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
• 5.4. Hospital Pharmacies
  • 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
• 5.5. Retail Pharmacies
  • 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
• 5.6. Online Pharmacies
  • 5.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 6. Eliquis (Apixaban) Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2033
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 6.4. North America
  • 6.4.1. North America Eliquis (Apixaban) Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Distribution Channel Disease Prevalence
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Framework
    • 6.4.2.5. U.S. Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Distribution Channel Disease Prevalence
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Framework
    • 6.4.3.5. U.S. Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Distribution Channel Disease Prevalence
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Framework
    • 6.4.4.5. Mexico Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Distribution Channel Disease Prevalence
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Framework
    • 6.5.2.5. UK Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Distribution Channel Disease Prevalence
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Framework
    • 6.5.3.5. Germany Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Distribution Channel Disease Prevalence
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement Framework
    • 6.5.4.5. France Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Distribution Channel Disease Prevalence
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Reimbursement Framework
    • 6.5.5.5. Italy Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Distribution Channel Disease Prevalence
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Framework
    • 6.5.6.5. Spain Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Distribution Channel Disease Prevalence
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Framework
    • 6.5.7.5. Denmark Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Distribution Channel Disease Prevalence
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement Framework
    • 6.5.8.5. Sweden Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Distribution Channel Disease Prevalence
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement Framework
    • 6.5.9.5. Norway Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Distribution Channel Disease Prevalence
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Framework
    • 6.6.2.5. Japan Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Distribution Channel Disease Prevalence
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Framework
    • 6.6.3.5. China Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Distribution Channel Disease Prevalence
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Framework
    • 6.6.4.5. India Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Distribution Channel Disease Prevalence
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Framework
    • 6.6.5.5. Australia Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Distribution Channel Disease Prevalence
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement Framework
    • 6.6.6.5. South Korea Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Distribution Channel Disease Prevalence
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement Framework
    • 6.6.7.5. Thailand Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Distribution Channel Disease Prevalence
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Framework
    • 6.7.2.5. Japan Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Distribution Channel Disease Prevalence
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Framework
    • 6.7.3.5. China Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Distribution Channel Disease Prevalence
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement Framework
    • 6.8.2.5. South Africa Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Distribution Channel Disease Prevalence
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement Framework
    • 6.8.3.5. Saudi Arabia Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Distribution Channel Disease Prevalence
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement Framework
    • 6.8.4.5. UAE Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Distribution Channel Disease Prevalence
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement Framework
    • 6.8.5.5. Kuwait Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. F. Hoffmann-La Roche Ltd.
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Mylan NV
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Teva Pharmaceutical Industries Ltd.
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Sanofi
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Pfizer Inc.
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. GSK plc
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Novartis AG
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. AstraZeneca
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Johnson & Johnson Private Limited
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Bristol-Myers Squibb Company
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives

관련자료